464 results about "Metastasis" patented technology

The invention provides a thyroid cancer auxiliary diagnosis and metastasis risk prediction method based on deep learning, and relates to the technical field of artificial intelligence auxiliary medical treatment, and the method comprises the steps: extracting ultrasonic image multi-scale features through a self-adaptive neural architecture search network, combining clinical examination data, fusing diagnosis and treatment knowledge through a neural symbol inference device, and carrying out the prediction of the metastasis risk. Generating a knowledge enhancement feature map; constructing a feature propagation field by using a dynamic neural field network, solving a dynamic evolution equation, and generating a spatial-temporal feature field representing the dynamic change of focus features; constructing a tumor diffusion kinetic model by using an implicit neural representation network and a nerve ordinary differential equation network, calculating a transition probability based on an optimal transmission algorithm, solving an optimal control equation, and outputting a metastasis risk prediction result of each organ; the thyroid cancer diagnosis accuracy and metastasis risk prediction reliability can be effectively improved, and doctors can be assisted in accurate diagnosis and treatment.

The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.

The invention relates to a hepatocellular carcinoma gene knockout target library based on multiple omics and a screening method of the hepatocellular carcinoma gene knockout target library, and the gene knockout target library for precise treatment of hepatocellular carcinoma is finally obtained through data collection and integration, data screening and target verification in sequence. According to the invention, through multi-omics data integration and bioinformatics analysis, key driving genes of hepatocellular carcinoma are systematically screened, and the important effects of the genes in occurrence, development, metastasis, drug resistance and immune escape of hepatocellular carcinoma are disclosed; the genes not only deepen the understanding of the hepatocellular carcinoma molecular mechanism, but also provide important theoretical basis and potential intervention targets for the development of targeted therapy and personalized therapy strategies.

The invention belongs to the technical field of anti-tumor, and discloses application of HP and ICT combined anti-PD-1 inhibitor hydrogel in residual cancer recurrence after IRFA. The excellent drug delivery capacity of the hydrogel system is utilized, and the in-vivo local slow release effect of ICT and BMS202 can be remarkably amplified. Through synergistic treatment of the TAN and the MDSC, local and whole body adaptive immunoreactions can be efficiently activated, TAN is effectively reprogrammed to be in a tumor suppression type, infiltration of PMN-MDSC is reduced, and the conclusion is verified in a plurality of mouse tumor models in the chapter. Therefore, the HP (at) ICT / BMS provides a promising delivery strategy for improving the sensitivity of anti-PD-L1 treatment and efficiently preventing and treating latent residual cancer and metastasis after IRFA operation.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention relates to the field of biological medicine, and provides application of a biheterocyclic derivative in treating breast cancer and serving as an antitumor drug sensitizer. The invention discloses application of a biheterocyclic derivative in inhibiting proliferation of breast cancer cells, inhibiting formation, growth and metastasis of breast cancer tumors and enhancing chemosensitivity of the breast cancer cells and the tumors. It is found for the first time that the compound can inhibit proliferation of breast cancer cells at low concentration without affecting normal cells, and chemosensitivity of the breast cancer cells is improved. The formation and growth of breast cancer tumors can be obviously inhibited at the concentration without obvious organ toxicity, and the chemosensitivity of the breast cancer tumors is enhanced. According to the invention, the anticancer activity and the chemotherapy sensitization effect of the compound can be clarified, and a pharmaceutical basis is provided for drug development in the field of breast cancer treatment.

The invention relates to the field of disease risk prediction models, and discloses a thyroid cancer metastasis risk prediction model and a construction method and application thereof. The construction method of the model comprises the following steps: S1, collecting and preprocessing a sample; s2, gene expression quantity detection; s3, data set division and standardization processing; s4, constructing a deep learning model; s5, performing model evaluation; and the biomarker group for detecting the gene expression quantity in the S2 is composed of RPS4Y1, PKHD1L1, CRABP1, KRT18P8, AGPAT4, CPQ, SLC26A7 and RBP4. The prediction model can be used as a clinical auxiliary diagnosis tool and is used for guiding operation range selection, postoperative follow-up visit strategy making and early intervention of high-risk patients, and the precise diagnosis and treatment level of thyroid cancer is improved.

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for detecting glycosylation modified RNA and application of the reagent in lung cancer metastasis prediction. According to the invention, glycosylation modification after RNA transcription is associated with the important pathological process of lung cancer metastasis for the first time, and a new theoretical basis and target are provided for diagnosis and treatment of lung cancer metastasis. In the prior art, the expression levels of genes and proteins are mainly concerned, and the invention goes deep into the RNA modification level and provides deeper and more accurate molecular information. And secondly, by detecting the glycosylation modification level of the LADENI, not only the expression quantity of the LADENI, the specificity and sensitivity of the LADENI as a biomarker are improved. The modification is dynamic and closely related to the function, so that the metastasis potential of the tumor cells can be reflected more accurately.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS. HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The invention belongs to the technical field of biological medicines, and particularly relates to application of a PPARalpha agonist combined with an NPC1L1 inhibitor in tumor treatment. Specifically, it is proved for the first time that systemic PKM2 deficiency can cause increase of the total cholesterol level and promote growth of homologous allograft tumors, and the phenomenon is partially attributed to increase of the expression level of intestinal NPC1L1. In addition, in breast cancer cells, PKM2 gene knockout not only weakens the activity of a PPARalpha signal channel, but also improves the expression of NPC1L1. Fenofibrate and Ezetimibe can be used for cooperatively inhibiting proliferation and metastasis of tumor cells in vitro and in vivo, so that the Fenofibrate and Ezetimibe have important clinical significance and social value.

The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a breast cancer or a pancreatic cancer). More specifically, the invention concerns the treatment of patients having cancer for the therapeutic inhibition of cancer cell growth and metastasis with an anti-Cadherin 11 monoclonal antibody with specific monoclonal antibody clones 23C6 or 3H10.

The present disclosure provides methods of treating or inhibiting cancer, reducing its severity, reducing its risk, or inhibiting its metastasis in an individual with a radiation-activated N-oxide TLR7 / 8 agonist.

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and / or optionally one or more additional anti-cancer agents.

The invention belongs to the technical field of early diagnosis of diseases, and discloses a polypeptide targeting macrophage PLIN2, a PET molecular probe and a preparation method and application thereof.Firstly, the polypeptide P672-1 targeting the PLIN2 is synthesized, and 64Cu-NOTA-P672-1 is prepared on the basis of the polypeptide P672-1. The molecular probe has the good chemical yield and stability, has the good targeting performance on the PLIN2, and can be used for preparing 64Cu-NOTA-P672-1. And the biological safety performance is good. Compared with the conventional 18F-FDG, the 64Cu-NOTA-P672-1 prepared by the preparation method disclosed by the invention has a good early diagnosis effect. The preparation method of the 64Cu-NOTA-P672-1 is simple and easy to implement, and the 64Cu-NOTA-P672-1 can be used for diagnosing early abdominal metastasis of ovarian cancer with high expression of PLIN2 The nuclide 64Cu-NOTA-P672-1 disclosed by the invention has important clinical significance on early diagnosis of ovarian cancer metastasis.

The invention discloses application of a substance for inhibiting MED10 protein activity and / or expression quantity in treatment of liver cancer. Experiments prove that the expression quantity of the MED10 protein and the encoding gene thereof in liver tissues or plasma of liver cancer patients is obviously higher than that of healthy people; by inhibiting the activity and / or expression quantity of the MED10 protein, proliferation of liver cancer cells can be inhibited, growth of the liver cancer cells can be inhibited, apoptosis of the liver cancer cells can be promoted, diffusion of the liver cancer cells can be inhibited, and metastasis of the liver cancer cells can be inhibited, so that the liver cancer can be treated. The method has an important application value.

The application relates to the field of biological medicine, and particularly relates to application of a TMEM119 gene or protein in development of an anti-gastric cancer drug, and particularly to application of a TMEM119 inhibitor in preparation of an anti-gastric cancer drug, wherein the inhibitor can be a small-molecule nucleotide for targeted knockdown of the TMEM119 gene or protein, the small-molecule nucleotide is shRNA or siRNA, the shRNA is a double-stranded oligonucleotide composed of complementary base sequences shown in SEQ ID NO. 1-2 or SEQ ID NO. 3-4; and the siRNA has a guide strand with a base sequence shown in SEQ ID NO. 7 or SEQ ID NO. 8. Experiments prove that when the expression of the TMEM119 gene of human gastric cancer cells is knocked down, the viability and the colony formation ability of the human gastric cancer cells are significantly reduced, thereby inhibiting the proliferation and survival of the gastric cancer cells, and further achieving the effect of restraining the occurrence, development, recurrence or metastasis of the gastric cancer.

The application provides an application of intracellular peroxide combined glutamine deprivation in an ACSL4-independent tumor cell metastasis inhibiting drug sensitive to ferroptosis. The technical problem in the prior art that ferroptosis tolerance is more conducive to tumor cell metastasis is solved, and a new intervention strategy for effectively inhibiting tumor cell metastasis with low ferroptosis sensitivity is developed.

The invention discloses an application of an ATGL inhibitor NG-497 in treatment of lung cancer / lung cancer metastasis. Researches prove that NG-497 can reduce the cell membrane fluidity and reduce the resistance of lung adenocarcinoma cells to fluid shear force by inhibiting decomposition of triglyceride, so that transfer of the lung adenocarcinoma cells is inhibited. The invention provides a potential new medicine and a new therapeutic target for lung cancer treatment or clinical treatment of lung cancer metastasis.

The application provides a kind of bacterial outer membrane vesicle based on acid-sensitive peptide label and its preparation method and application, it is related to the technical field of engineered bacterial outer membrane vesicle.The ClyA-pHLIP fusion protein is designed and synthesized in the application, and the pHA-W3110OMV stably expressing the ClyA-pHLIP fusion protein is successfully obtained by using genetic engineering technology.The pHA-W3110OMV effectively solves the problem of easy aggregation of pHLIP in acidic environment, has good stability and solubility, and provides conditions for the stable targeting performance of pHLIP.Meanwhile, the pHA-W3110OMV not only retains the characteristics of targeting tumor cells in acidic environment, but also realizes the characteristics of targeting tumor cells in non-acidic environment.The pHA-W3110OMV has high targeting tracing efficiency on tumor cells under different pH conditions, and can realize qualitative and quantitative detection of tumor cells in peripheral blood, and has application potential in circulating tumor cell detection and tumor primary and metastasis localization.

The invention discloses a human-derived ampulla cancer cell line DPC-X5 and application thereof, and belongs to the field of microbial animal cell lines. The human-derived ampulla cancer cell line is named as a human-derived ampulla cancer cell line (homo sapiens) DPC-X5, and is preserved in the China Center for Type Culture Collection on October 30, 2025, and the preservation number is CCTCC NO: C202580. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of a cell model for occurrence, development or metastasis of ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to cell models for researching differentiation mechanisms, cell morphology and dysfunction and tumor infiltration and metastasis mechanisms of ampulla cancer and guiding clinical comprehensive diagnosis and treatment. The human-derived ampulla cancer cell line DPC-X5 can be applied to research on the occurrence mechanism of the ampulla cancer and screening of drugs for preventing and treating the ampulla cancer. The human-derived ampulla cancer cell line DPC-X5 can be applied to establishment of an ampulla cancer animal model.

The invention relates to the field of biotechnology and medicine, and discloses a polypeptide targeting molecular chaperonin TRIC / CCT and application thereof. The sequence of the polypeptide is consistent with or truncated from the C-terminal sequence of a CCT subunit, and the polypeptide can be competitively combined with CRL4-DCAF12 ubiquitin ligase, so that the ubiquitination of the CCT subunit is reduced, and the formation of a TRIC / CCT compound is inhibited; the polypeptide inhibits the formation of a TRIC / CCT compound and blocks the activation of key metastasis promoting signal channels such as YAP, STAT3 and mTOR, thereby inhibiting the metastasis of lung cancer. According to systematic in-vivo and in-vitro experiments, the compound has excellent performance in the aspect of inhibiting lung cancer cell migration and metastasis, has the characteristics of clear target spot, clear action mechanism and the like, and provides a new treatment strategy for developing a new generation of lung cancer metastasis resisting medicines.

The present application relates to a kind of pharmaceutical composition for treating advanced gastric cancer, in particular, the pharmaceutical composition of pill soup stacking medicine method.The composition includes radix astragali, pungent turmeric, radix comphorae etc.Ingredients are mixed into decoction according to specific proportion, combined with Xi Huang pill and apatinib.The decoction has the effect of strengthening body resistance and consolidating foundation, while the pill is mainly used to attack and remove the metastasis into collaterals, and remove stasis and toxicant to eliminate mass.A series of clinical cases verify that the therapy shows significant efficacy on patients with advanced gastric cancer, and no serious adverse reactions are found.

The application provides a polypeptide vaccine delivery carrier, which is a phenylalanine-based polyester amide polymer prepared from triethylamine, p-nitrophenol, L-phenylalanine and butanediol. + The polypeptide vaccine has good stability, high antigen presentation effect, and can induce the body to produce effective antitumor CD8 T cell immune response, inhibit tumor growth and metastasis, and improve the effect of immunotherapy.

The embodiment of the invention discloses application of ALDH3A2 as a target spot in preparation of a medicine for treating gastric cancer. The research clarifies a new effect and a potential mechanism of ALDH3A2 in the aspect of inhibiting gastric cancer progression. Specifically, the ALDH3A2 can be used for down-regulating the expression of SLC47A1, so that the nuclear transfer of NRF2 is prevented, and the activation of UPRmt is inhibited. The damage can aggravate mitochondrial dysfunction, and finally, gastric cancer cell ferroptosis is promoted in a glutathione peroxidase 4 (GPX4) dependent mode. In addition, ferroptosis induced by ALDH3A2 can also promote polarization of macrophages to M1 type, and the progress of gastric cancer cells is inhibited through an IL-1beta signal channel. In conclusion, the effects jointly inhibit proliferation, migration and invasion of gastric cancer cells, and finally inhibition of growth and metastasis of gastric cancer is achieved.

The present disclosure provides methods to assess lymph node samples such as endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples to determine sample sufficiency and / or to detect metastasis in mediastinal lymph nodes using lymph node biomarkers. Also provided are devices and kits that can be used to perform the methods disclosed herein.

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.

This application relates to the field of biotechnology, specifically disclosing the application of immune cell subsets in the preparation of detection products for assessing the efficacy of neoadjuvant therapy and the risk of recurrence and metastasis in breast cancer. The detection method described in this application is non-invasive and convenient, requiring only peripheral blood, and is easy to repeat sampling and dynamic monitoring. This application also provides a predictive model for the efficacy of neoadjuvant therapy in breast cancer, and a predictive model for the risk of recurrence and metastasis in breast cancer treated with neoadjuvant therapy. The constructed predictive model has a high AUC value (0.82-0.87), and good sensitivity and specificity. Furthermore, through regular postoperative monitoring, abnormal dynamic changes in immune cell subsets can be detected, potentially indicating signs of recurrence earlier than imaging and traditional tumor markers. This helps identify advantageous populations before treatment and high-risk populations after treatment, enabling optimization of treatment plans and individualized adjustment of follow-up density.